PT  - JOURNAL ARTICLE
AU  - SYSEL, ANNETTE M.
AU  - HORNE, WALTER I.
AU  - STEINER, JÖRG M.
AU  - SUCHODOLSKI, JAN S.
AU  - BAUER, JOSEPH A.
TI  - Pharmacokinetics of Intravenous Nitrosylcobalamin, an Antitumor Agent, in Healthy Beagle Dogs: A Pilot Study
DP  - 2012 Sep 01
TA  - Anticancer Research
PG  - 3749--3752
VI  - 32
IP  - 9
4099  - http://ar.iiarjournals.org/content/32/9/3749.short
4100  - http://ar.iiarjournals.org/content/32/9/3749.full
SO  - Anticancer Res2012 Sep 01; 32
AB  - Background/Aim: Nitrosylcobalamin (NO-Cbl) is a cobalamin-based anti-tumor agent. This study evaluated the pharmacokinetic parameters of NO-Cbl following intravenous administration in dogs. Materials and Methods: Four dogs received 10 mg/kg, 20 mg/kg and 40 mg/kg intravenous bolus doses of NO-Cbl, with a 14-day washout period between doses. Blood samples were collected at baseline and post-dosing, and noncompartmental pharmacokinetic parameters were determined. Results: Average peak serum concentrations of 2265, 5523 and 13,866 pg/mL were achieved following single-dose bolus intravenous administration of 10 mg/kg, 20 mg/kg and 40 mg/kg of NO-Cbl respectively. The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively. Conclusion: These results can be used to determine the dose and dosing intervals for clinical trials evaluating NO-Cbl in humans and companion animals.